These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
179 related items for PubMed ID: 31858313
1. Current Perspectives on Ligand-Binding Assay Practices in the Quantification of Circulating Therapeutic Proteins for Biosimilar Biological Product Development. Thway TM, Wang YM, Booth BP, Maxfield K, Huang SM, Zineh I. AAPS J; 2019 Dec 19; 22(1):15. PubMed ID: 31858313 [Abstract] [Full Text] [Related]
2. Retrospective Analysis of Bioanalytical Method Validation Approaches in Biosimilar Biological Product Development. Obianom ON, Thway TM, Schrieber SJ, Okusanya OO, Wang YM, Huang SM, Zineh I. AAPS J; 2019 Sep 11; 21(6):105. PubMed ID: 31512109 [Abstract] [Full Text] [Related]
3. Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs. Colbert A, Umble-Romero A, Prokop S, Chow VF, Wong T, DeSimone D, Zhou L, Pederson S. MAbs; 2014 Sep 11; 6(5):1178-89. PubMed ID: 25517303 [Abstract] [Full Text] [Related]
4. Systematic verification of bioanalytical similarity between a biosimilar and a reference biotherapeutic: committee recommendations for the development and validation of a single ligand-binding assay to support pharmacokinetic assessments. Marini JC, Anderson M, Cai XY, Chappell J, Coffey T, Gouty D, Kasinath A, Koppenburg V, Oldfield P, Rebarchak S, Bowsher RR. AAPS J; 2014 Nov 11; 16(6):1149-58. PubMed ID: 25277165 [Abstract] [Full Text] [Related]
5. A Simulation Approach to Evaluate the Impact of Patterns of Bioanalytical Bias Difference on the Outcome of Pharmacokinetic Similarity Studies. Obianom ON, Okusanya OO, Earp J, Thway TM. Clin Pharmacol Ther; 2020 Jul 11; 108(1):107-115. PubMed ID: 31957006 [Abstract] [Full Text] [Related]
7. Bioanalytical challenges of biosimilars. Islam R. Bioanalysis; 2014 Feb 11; 6(3):349-56. PubMed ID: 24471955 [Abstract] [Full Text] [Related]
8. International standards for monoclonal antibodies to support pre- and post-marketing product consistency: Evaluation of a candidate international standard for the bioactivities of rituximab. Prior S, Hufton SE, Fox B, Dougall T, Rigsby P, Bristow A, participants of the study. MAbs; 2018 Jan 11; 10(1):129-142. PubMed ID: 28985159 [Abstract] [Full Text] [Related]
14. Challenges in bioanalytical assays for biosimilars. Wang X, Chen L. Bioanalysis; 2014 Aug 11; 6(16):2111-3. PubMed ID: 25331854 [No Abstract] [Full Text] [Related]
17. Regulatory considerations for development of bioanalytical assays for biotechnology products. Swann PG, Shapiro MA. Bioanalysis; 2011 Mar 11; 3(6):597-603. PubMed ID: 21417729 [Abstract] [Full Text] [Related]
18. Demonstrating biosimilar and originator antidrug antibody binding comparability in antidrug antibody assays: a practical approach. Ryding J, Stahl M, Ullmann M. Bioanalysis; 2017 Sep 11; 9(18):1395-1406. PubMed ID: 28920451 [Abstract] [Full Text] [Related]
19. Role of Modeling and Simulation in the Development of Novel and Biosimilar Therapeutic Proteins. Wang YC, Wang Y, Schrieber SJ, Earp J, Thway TM, Huang SM, Zineh I, Christl L. J Pharm Sci; 2019 Jan 11; 108(1):73-77. PubMed ID: 30395832 [Abstract] [Full Text] [Related]